You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


Advertisement

ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | RSS | Access Rights | Sign In


  Vol. 151 No. 5, MAY 1991 TABLE OF CONTENTS
  Online Only
 •  Online First Table of
Contents
  REVIEW ARTICLES
 •Online Features
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (35)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Delicious Add to Digg Add to Facebook Add to Reddit Add to Technorati Add to Twitter What's this?

Mechanisms of Bacterial Resistance to Antibiotics

Laura A. Dever, RPh; Terence S. Dermody, MD

Arch Intern Med. 1991;151(5):886-895.


Abstract



The three fundamental mechanisms of antimicrobial resistance are (1) enzymatic degradation of antibacterial drugs, (2) alteration of bacterial proteins that are antimicrobial targets, and (3) changes in membrane permeability to antibiotics. Antibiotic resistance can be either plasmid mediated or maintained on the bacterial chromosome. The most important mechanism of resistance to the penicillins and cephalosporins is antibiotic hydrolysis mediated by the bacterial enzyme β-lactamase. The expression of chromosomal β-lactamase can either be induced or stably derepressed by exposure to β-lactam drugs. Methods to overcome resistance to β-lactam antibiotics include the development of new antibiotics that are stable to β-lactamase attack and the coadministration of β-lactamase inhibitors with β-lactam drugs. Resistance to methicillin, which is stable to gram-positive β-lactamase, occurs through the alteration of an antibiotic target protein, penicillin-binding protein 2. Production of antibioticmodifying enzymes and synthesis of antibiotic-insensitive bacterial targets are the primary resistance mechanisms for the other classes of antibiotics, including trimethoprim, the sulfonamides, the aminoglycosides, chloramphenicol, and the quinolone drugs. Reduced antibiotic penetration is also a resistance mechanism for several classes of antibiotics, including the β-lactam drugs, the aminoglycosides, chloramphenicol, and the quinolones.

(Arch Intern Med. 1991;151:886-895)



Author Affiliations



From the Pharmacy Department, New England Medical Center (Ms Dever); Department of Microbiology and Molecular Genetics, Harvard Medical School (Dr Dermody); and Department of Medicine, Brigham and Women's Hospital (Dr Dermody), Boston, Mass. Dr Dermody is now with the Department of Pediatric Infectious Diseases, Vanderbilt University Medical Center, Nashville, Tenn.


Footnotes



Accepted for publication October 16, 1990.

Reprint requests to Department of Pediatric Infectious Diseases, Vanderbilt University Medical Center, Nashville, TN 37232 (Dr Dermody).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Delicious Delicious   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

CmeABC Functions as a Multidrug Efflux System in Campylobacter jejuni
Lin et al.
Antimicrob. Agents Chemother. 2002;46:2124-2131.
ABSTRACT | FULL TEXT  

A SURVEY OF ANTIBIOTIC USE IN DENTISTRY
EPSTEIN et al.
Journal of the American Dental Association 2000;131:1600-1609.
ABSTRACT | FULL TEXT  

Novel beta -Lactamase Genes from Two Environmental Isolates of Vibrio harveyi
Teo et al.
Antimicrob. Agents Chemother. 2000;44:1309-1314.
ABSTRACT | FULL TEXT  

Therapeutic Drug Monitoring of Therapy for Infectious Diseases
Oliphant
Journal of Pharmacy Practice 1997;10:7-19.
ABSTRACT  

Therapeutic Drug Monitoring of Therapy for Infectious Diseases
Oliphant
Journal of Pharmacy Practice 1995;8:18-28.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | PHYSICIAN JOBS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1991 American Medical Association. All Rights Reserved.